AbbVie (ABBV) Receives a Buy from RBC Capital
In a report released today, Trung Huynh from RBC Capital maintained a Buy rating on AbbVie, with a price target of $260.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Huynh is a 5-star analyst with an average return of 27.1% and a 74.40% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol-Myers Squibb.
In addition to RBC Capital, AbbVie also received a Buy from Guggenheim’s Vamil Divan in a report issued today. However, on April 8, TipRanks – OpenAI reiterated a Hold rating on AbbVie (NYSE: ABBV).
Based on AbbVie’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $16.62 billion and a net profit of $1.82 billion. In comparison, last year the company earned a revenue of $15.1 billion and had a GAAP net loss of $22 million
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABBV in relation to earlier this year. Last month, David Ryan Purdue, the SVP, Controller of ABBV sold 5,230.00 shares for a total of $1,221,518.80.
Read More on ABBV:
